Stocks and sectors moved sharply in midday trading as investors reacted to earnings results, corporate financing plans and deal-related news. Oracle slid after filing plans to raise capital for its artificial intelligence build-out, while IDEXX Laboratories and Tempus AI gained following results that beat estimates and came with updated guidance. In tech and industrials, memory and semiconductor shares weighed on broader sentiment as market participants digested ongoing weakness and a major acquisition agreement.
Key takeaways
- Oracle shares dropped about 6% after the company filed plans to issue $10 billion of common stock and $10 billion of senior notes to fund its AI expansion.
- IDEXX climbed roughly 20% after third-quarter revenue and earnings exceeded expectations, prompting the company to raise its 2026 outlook.
- Tempus AI rose nearly 12% as it posted beats on revenue and adjusted EBITDA and increased its 2026 revenue forecast.
- Memory stocks fell 3% to 5% with Micron, SanDisk and Western Digital continuing a prior sell-off.
- Marvell slid about 9% and Lumentum fell about 15% following news of Marvell’s planned all-stock acquisition valued at $115 billion, expected to close in the first half of 2028.
Company results drive gains in healthcare and software
Oracle was the standout decliner. The database software company fell about 6% after filings showed it plans to issue $10 billion in common stock and $10 billion in senior notes, according to its SEC documentation. Investors typically scrutinize these moves because large capital raises can dilute existing shareholders and increase leverage, even when management ties the financing to a growth initiative such as AI build-out.
In contrast, IDEXX Laboratories advanced about 20% after it topped third-quarter earnings and revenue expectations. The company reported third-quarter revenue of $1.21 billion, about 10% higher than the year-earlier period, with growth attributed to its Companion Animal Group. IDEXX also raised its 2026 revenue and earnings forecasts while lowering its operating-margin outlook, suggesting management is balancing top-line momentum with margin discipline.
Tempus AI gained nearly 12% after it reported results that beat Wall Street estimates. The precision-medicine company’s revenue rose 23% to $411.5 million. It cited growth in data and applications of 33%, while oncology volume growth accelerated to 32%. Tempus also increased its 2026 revenue forecast and reiterated its adjusted EBITDA outlook, reinforcing investor confidence that operating progress can be sustained beyond a single quarter.
Deal headlines and financing plans reshape sentiment
Space and communications-related momentum also appeared in the tape. SpaceX shares rose more than 3% after The Washington Post reported the rocket and satellite company is in talks involving Dish Network’s Boost Mobile subsidiary or could use Dish’s network. The paper said a deal could provide CEO Elon Musk a route into the broader wireless market. While details remain unconfirmed, the market response suggests investors view network access as a potential strategic lever for future growth.
In electric vehicles, Rivian climbed about 10% after an upgrade to buy from UBS. Analyst Joseph Spak said Rivian’s recent sell-off creates a potential entry point ahead of what he described as an inflection in sales of the company’s R2 midsize SUV. Upgrades of this nature often matter most when the market has already discounted near-term uncertainty, making forward catalysts—like improving sales trajectories—more likely to move sentiment.
Semiconductors and optical technology were pressured by acquisition news. Marvell slid about 9% and Lumentum fell about 15% after Marvell agreed to buy the high-performance laser maker in an all-stock deal valued at $115 billion. The transaction is expected to close in the first half of 2028. An all-stock structure can introduce dilution risk for the acquirer’s shareholders, and the market reaction also reflects the likelihood of integration costs and execution uncertainty across the multi-year timeline to completion.
Memory weakness and energy pullback weigh on the broader tape
Memory-related stocks continued to underperform. Micron, SanDisk and Western Digital each fell roughly 3% to 5%, extending a decline that started Friday. Investors typically interpret renewed weakness in memory as a signal that demand expectations or pricing for memory products are not stabilizing as quickly as hoped, even when individual companies may report idiosyncratic progress.
Energy names also softened as oil prices declined early in the week. ExxonMobil, Chevron and Valero each pulled back about 3% to 5%, reflecting how equity performance in the sector often tracks changes in crude pricing. A drop in oil can pressure earnings expectations and near-term cash flow outlooks, particularly for refiners and integrated producers with sensitivity to commodity swings.
Krystal Biotech was the sharpest drag in the biotech cohort. Shares plunged nearly 15% after the company said data for several treatments would be pushed back to 2027, including results for its KB801 gene therapy for neurotrophic keratitis. The delay overshadowed a third-quarter beat on both top and bottom lines versus FactSet consensus estimates. Investors generally weigh timing risk heavily in biotech because delayed readouts can shift expected catalysts and affect capital planning and valuation narratives.
What to watch next
With company-specific catalysts driving today’s moves, investors will likely focus on whether guidance changes translate into durable earnings trajectories—especially for AI financing plans, memory demand, and merger execution timelines. Over the coming sessions, market attention should turn to upcoming corporate updates and broader macro drivers that can influence risk appetite, including interest-rate expectations and fresh data that could affect discount rates for growth stocks.
